Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Is ABO Blood Group a CV Risk Factor in FH Patients?

J Clin Lipidol; ePub 2017 Dec 13; Paquette, et al

A non-O blood group is associated with an independent 2-fold increased risk of cardiovascular disease (CVD) in patients with familial hypercholesterolemia (FH), a recent study found. The study examined the effect of the ABO blood group on CVD risk in 668 adult participants with a heterozygous FH-causing mutation in the low-density lipoprotein receptor (LDLR) gene. ABO blood group was determined using 2 functional single-nucleotide polymorphisms in the ABO gene. Researchers found:

  • Total cholesterol was significantly higher in non-O subjects compared to carriers of the O group.
  • A greater proportion of participants carrying the non-O groups was observed in patients with CVD vs those without CVD (73.4% vs 63.3%).
  • The non-O group was significantly associated with an increased prevalence of CVD (odds ratio, 2.14).
  • Patients in the non-O blood group experienced more CVD events vs those in the O group (0.88 per individual vs 0.60).

Citation:

Paquette M, Dufour R, Baass A. ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia. [Published online ahead of print December 13, 2017]. J Clin Lipidol. doi:10.1016/j.jacl.2017.12.001.

This Week's Must Reads

Evolocumab Lowers LDL-C in Patient Subgroups, Clin Cardiol; 2018 Oct 21; Stroes, Robinson, et al

Is Further Lowering of LDL-C in Patients Safe?, JAMA Cardiol; 2018 Sep; Sabatine, Wiviott, et al

Effects of Primary Prevention on CVD Event Risk, J Manag Care Spec Pharm; 2018 Nov; Han, et al

FH Patients with Diabetes at Elevated Risk for CVD, J Clin Lipidol; ePub 2018 Sep 17; Paquette, et al

Long-Term Benefit to Statin Eligibility, JAMA Cardiol; ePub 2018 Oct 24; Thanassoulis, et al

Must Reads in Hypercholesterolemia

Evolocumab Lowers LDL-C in Patient Subgroups, Clin Cardiol; 2018 Oct 21; Stroes, Robinson, et al

Is Further Lowering of LDL-C in Patients Safe?, JAMA Cardiol; 2018 Sep; Sabatine, Wiviott, et al

Effects of Primary Prevention on CVD Event Risk, J Manag Care Spec Pharm; 2018 Nov; Han, et al

FH Patients with Diabetes at Elevated Risk for CVD, J Clin Lipidol; ePub 2018 Sep 17; Paquette, et al

Long-Term Benefit to Statin Eligibility, JAMA Cardiol; ePub 2018 Oct 24; Thanassoulis, et al